Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251545 | 0.88 | NPBWR1 (0.35) | NPBWR1TSHRALDH1A1KDM4EMAPT | |
| SCHEMBL4447381 | 0.82 | PKM (0.37) | NPBWR1ALDH1A1KDM4EGAA | |
| SCHEMBL4257857 | 0.76 | NPBWR1 (0.45) | NPBWR1TSHRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4257924 | 0.72 | HTT (0.41) | NPBWR1CYP3A4CYP2C19MEN1KMT2A | |
| SCHEMBL4250398 | 0.71 | CASP3 (0.41) | NPBWR1IDO1TDO2 | |
| SCHEMBL13608160 | 0.71 | CASP3 (0.41) | NPBWR1IDO1TDO2 | |
| SCHEMBL4451133 | 0.71 | PKM (0.42) | NPBWR1ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL4253900 | 0.69 | LMNA (0.36) | TSHRMEN1KMT2AALDH1A1GAA | |
| SCHEMBL4253480 | 0.69 | ALDH1A1 (0.40) | NPBWR1TSHRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4255978 | 0.68 | NPBWR1 (0.38) | NPBWR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481537-B2 | Caspase inhibitors based of pyridazinone scaffold | LG LIFE SCIENCES LTD. (KR) | 2013-07-09 | — | — | US | disclosed |
| US-20090291959-A1 | CASPASE INHIBITORS BASED OF PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2009-11-26 | — | — | US | disclosed |
| EP-2046757-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG Life Sciences Ltd. (KR) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008016239-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291959-A1 | CASPASE INHIBITORS BASED OF PYRIDAZINONE SCAFFOLD | CASP1, CASP2, CASP5 | NPBWR1 4356/4885TSHR 4747/4885CYP3A4 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.